2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 8, 2015

2:30PM-4:00PM: Abstract Number: 974

Secukinumab Significantly Improves Signs and Symptoms of Active Ankylosing Spondylitis: 52-Week Results from a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial with Subcutaneous Loading and Maintenance Dosing

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Treatment of AS

2:30PM-4:00PM: Abstract Number: 909

Smoking Behavior Changes after Rheumatoid Arthritis Diagnosis and Risk of Mortality during 36 Years of Prospective Follow-up

Epidemiology and Public Health I: RA Comorbidities and Mortality

2:30PM-4:00PM: Abstract Number: 994

Th17/Tfh Cell Predict Disease Severity in Rheumatoid Arthritis Patients Receiving TNF Inhibitor Therapy

T cell Biology and Targets in Autoimmune Disease I

2:30PM-4:00PM: Abstract Number: 956

The Addition of One or More Biologics to Methotrexate in Children with Juvenile Idiopathic Arthritis Increases the Incidence of Infections and Other Adverse Events

Pediatric Rheumatology - Clinical and Therapeutic Aspects I: Juvenile Idiopathic Arthritis

2:30PM-4:00PM: Abstract Number: 975

The Effect of TNF Inhibition on Radiographic Progression in Ankylosing Spondylitis: An Observational Cohort Study of 374 Patients

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Treatment of AS

2:30PM-4:00PM: Abstract Number: 973

The Effect of TNF Inhibitor Treatment on Occurrence of Anterior Uveitis in Ankylosing Spondylitis: Results from the Swedish Biologics Register

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Treatment of AS

2:30PM-4:00PM: Abstract Number: 949

The Metabolic Syndrome, Its Elements and Knee Osteoarthritis: The Framingham Osteoarthritis (OA) Study

Osteoarthritis - Clinical Aspects: Treatments and Epidemiology

2:30PM-4:00PM: Abstract Number: 907

The Natural History of an Inception Cohort of Patients with Inflammatory Polyarthritis Followed for 20 Years: Disease Activity, Disability and Surgery

Epidemiology and Public Health I: RA Comorbidities and Mortality

2:30PM-4:00PM: Abstract Number: 976

The Reason of Discontinuation of a First TNF Inhibitor Affects Drug Retention of a Second Anti-TNF Agent in Axial Spondyloarthritis

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Treatment of AS

2:30PM-4:00PM: Abstract Number: 954

The Relationship Between Osteoarthritis and Cardiovascular Disease: Results from a Population-Based Cohort

Osteoarthritis - Clinical Aspects: Treatments and Epidemiology

2:30PM-4:00PM: Abstract Number: 958

The Time Spent in Inactive Disease before MTX Withdrawal Is Relevant with Regard to the Recurrence of Active Disease in Juvenile Idiopathic Arthritis (JIA) Patients

Pediatric Rheumatology - Clinical and Therapeutic Aspects I: Juvenile Idiopathic Arthritis

2:30PM-4:00PM: Abstract Number: 928

The Value of Early Ultrasound-Detected Osteophytes in Hand Osteoarthritis: Predicting the Future

Imaging of Rheumatic Diseases I: Ultrasound

2:30PM-4:00PM: Abstract Number: 992

Therapeutic Targeting of CD4+ T Cell Metabolism in Murine Models of Lupus

T cell Biology and Targets in Autoimmune Disease I

2:30PM-4:00PM: Abstract Number: 984

Tofacitinib Inhibits Inflammation and New Bone Formation in Murine Spondyloarthritis but Does Not Adversely Inhibit Normal Human MSC Function

Spondylarthropathies Psoriatic Arthritis - Pathogenesis, Etiology

2:30PM-4:00PM: Abstract Number: 910

Tumor Necrosis Factor-Alpha Inhibitor Use and the Risk of Incident Hypertension in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study

Epidemiology and Public Health I: RA Comorbidities and Mortality

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].